Objective: It has not been solved whether subjects carrying the minor alleles of the À455T4C or À482C4T single nucleotide polymorphisms (SNPs) in the apolipoprotein-C3-gene (APOC3) have an increased risk for developing fatty liver and insulin resistance. We investigated the relationships of the SNPs with hepatic APOC3 expression and hypothesized that visceral obesity may modulate the effects of these SNPs on liver fat and insulin sensitivity (IS). Methods: APOC3 mRNA expression and triglyceride content were determined in liver biopsies from 50 subjects. In a separate group (N ¼ 330) liver fat was measured by 1 H-magnetic resonance spectroscopy. IS was estimated during an oral glucose tolerance test (OGTT) and the euglycemic, hyperinsulinemic clamp (N ¼ 222). Results: APOC3 mRNA correlated positively with triglyceride content in liver biopsies (r ¼ 0.29, P ¼ 0.036). Carriers of the minor alleles (À455C and À482T) tended to have higher hepatic APOC3 mRNA expression (1.80 (0.45-3.56) vs 0.77 (0.40-1.64), P ¼ 0.09), but not higher triglyceride content (P ¼ 0.76). In 330 subjects the genotype did not correlate with liver fat (P ¼ 0.97) or IS (OGTT: P ¼ 0.41; clamp: P ¼ 0.99). However, a significant interaction of the genotype with waist circumference in determining liver fat was detected (P ¼ 0.02) in which minor allele carriers had higher liver fat only in the lowest tertile of waist circumference (P ¼ 0.01). In agreement, during a 9-month lifestyle intervention the minor allele carriers of the SNP À482C4T in the lowest tertile also had less decrease in liver fat (P ¼ 0.04). Conclusions: APOC3 mRNA expression is increased in fatty liver and is regulated by SNPs in APOC3. The impact of the APOC3 SNPs on fatty liver is small and depends on visceral obesity.
Introduction
Non-alcoholic fatty liver disease (NAFLD) strongly associates with insulin resistance and atherosclerosis, independent of other risk factors such as total-and visceral adiposity. [1] [2] [3] [4] [5] [6] [7] [8] [9] Furthermore, NAFLD is thought to be directly involved in the pathogenesis of both, liver-specific diseases as fibrosis, cirrhosis and hepatocellular carcinoma, and type 2 diabetes and cardiovascular disease. [10] [11] [12] [13] [14] [15] Therefore, fatty liver became the subject of intensive ongoing research focusing on environmental and genetic causes, as well as on treatment 16, 17 of hepatic steatosis.
Although in animals several genes were found to be involved in the development of NAFLD, [2] [3] [4] in humans there is still limited information about such major genes. 18, 19 In 2008, genome-wide association scans identified patatinlike phospholipase 3 (PNPLA3), a by then in this respect unrecognized gene, to be associated with hepatic steatosis. 20 Interestingly, this gene appears to be among the strongest genes regulating fat accumulation in the liver, yet not insulin resistance. [20] [21] [22] In 2010 apolipoprotein C3 (APOC3) was proposed as another candidate gene for fatty liver. APOC3 is a component of triglyceride-rich lipoproteins that impairs the clearance of these particles from the circulation, which results in increased plasma triglyceride concentrations. [23] [24] [25] Common mutations in the APOC3 promoter (À455T4C and À482C4T), were found to associated with higher plasma triglycerides, [26] [27] [28] APOC3 concentrations 29 and increased risk of CHD. 26, 28, 30 These single nucleotide polymorphisms (SNPs) are located within an insulin responsive element in the APOC3 promoter and result in overexpression of APOC3 due to attenuated suppression by insulin. 27 Asian-Indian men carrying at least one of the minor alleles of the rs3854116 (À455T4C) or the rs2854117 (À482C4T) SNPs in the apolipoprotein C3 gene (APOC3) were found to have higher liver fat content than homozygous carriers of both major alleles. 31 In the same study similar findings were observed for non-Asian Indian men. These data suggested that APOC3 may also be involved in the pathogenesis of fatty liver. Furthermore, because none of the subjects carrying the protective genotype were found in the group of subjects with NAFLD, it was also concluded that carriers of the minor alleles are insulin resistant. 31 However, the association of the genotype with insulin sensitivity (IS) was not specifically tested in that study. In contrast, in a large study including three populations, the SNPs were not associated with liver fat content or with IS. 32 The different findings underline the need for further studies precisely investigating gene-gene and gene-environmental interactions of this genotype in determining fatty liver and metabolic traits. 33 Indeed, the same SNPs were previously found to strongly affect serum trigyceride levels and to predict cardiovascular events, 26, 34 however, only in subjects without visceral obesity. 34 Consequently, to study more in detail the possible role of these SNPs in the pathogenesis of fatty liver and insulin resistance, we first investigated the associations of mRNA expression of APOC3 with triglyceride content in human liver tissue. Second, we tested whether the SNPs are associated with APOC3 mRNA expression and with triglyceride content in these liver samples. Third, we investigated whether the SNPs are associated with liver fat, measured by 1 H-magnetic resonance spectroscopy, with total body-and visceral fat, with IS, measured during a 2-h 75 g glucose tolerance test (OGTT) and during the euglycemic, hyperinsulinemic clamp and tested whether such relationships depend on visceral obesity.
Subjects and methods

Subjects
Data from 330 Caucasians of the southern part of Germany who participated in an ongoing study on the pathophysiology of type 2 diabetes and from whom information about relationships of genetic variability in PNPLA3 with liver fat and IS were previously reported, 21 were included in this analysis. In brief, individuals were recruited to participate in the study when they fulfilled at least one of the following criteria: a family history of type 2 diabetes, a body mass index (BMI) 427 kg m
À2
, previous diagnosis of impaired glucose tolerance or gestational diabetes. 17 All subjects had measurements of body fat distribution determined by magnetic resonance imaging. They were included into the study when no considerable abnormalities in blood count, blood coagulation, kidney or liver function or acute inflammatory processes were apparent according to a physical examination and routine laboratory tests. Also, as assessed by means of a standard questionnaire, the participants had no history of liver disease such as hepatitis, and did not consume more than two alcoholic drinks per day. Among these subjects, 223 participated in an ongoing lifestyle intervention for a mean of 9 months and had measurements of liver fat content at baseline and at followup. 17 After the baseline measurements, individuals underwent dietary counseling and had up to 10 sessions with a dietitian. During each visit participants presented a 3-day food diary and discussed the results with the dietitians. Counseling was aimed to reduce body weight by X5%, to reduce the intake of energy from fat to o30% and particularly the intake of saturated fat to p10% of energy consumed and to increase the intake of fibre to at least 15 g per 4184 kJ (1000 kcal). Individuals were asked to perform at least 3 h of physical activities per week. Participants were seen by the staff on a regular basis to ensure that these recommendations were followed. 17 In addition, data from a separate group of 50 Caucasians (19F/31M, age 64±12 years, BMI 25±4 kg m
) undergoing liver surgery in the Department of General, Visceral and Transplant Surgery, at the University of Tübingen, were included in the present study. Indications for the surgery were hepatic hemangioma, curative resection of hepatic metastases of colorectal malignancies or hepatocellular carcinoma. Liver samples were taken from normal, non-diseased tissue during surgery. Patients were fasted over night prior to collection of the liver biopsies. Subjects tested negative for viral hepatitis and had no liver cirrhosis. Informed written consent was obtained from all participants and the local medical ethics committee had approved the protocol.
Body fat distribution and liver fat Waist circumference was measured at the midpoint between the lateral iliac crest and lowest rib. Furthermore, we measured total body-and visceral fat with an axial T1-weighed fast spin echo technique with a 1.5T wholebody imager (Magnetom Sonata, Siemens Medical Solutions, Erlangen, Germany) and liver fat by localized 1 HMR spectroscopy, as previously described. 17, 35 OGTT and euglycemic, hyperinsulinemic clamp Individuals underwent a 75-g OGTT. We obtained venous plasma samples at 0, 30, 60, 90 and 120 min for determination of plasma glucose and insulin. IS from the OGTT was estimated as proposed by Matsuda and DeFronzo. 36 Furthermore, the homeostasis model assessment of insulin 
Liver samples
Liver samples were taken from normal, non-diseased tissue during surgery, immediately frozen in liquid nitrogen and stored at À80 1C. Tissue samples were homogenized in phosphate-buffered saline containing 1% Triton X-100 using a TissueLyser (Qiagen, Hilden, Germany) and triglyceride content was quantified using the ADVIA 1650 clinical chemistry analyzer (Siemens Healthcare Diagnostics) and calculated as percentage (mg per 100 mg tissue). For the determination of hepatic mRNA expression by quantitative PCR analysis frozen tissue was homogenized in a TissueLyser and RNA was extracted with the RNeasy Tissue Kit (Qiagen) according to the manufacturer's instructions. Reverse transcription of total RNA and quantitative PCR of b-actin was performed on the LightCycler 480 system (Roche Diagnostics, Mannheim, Germany) with SYBR Green. Expression of APOC3 was performed using a QuantiTect SYBR Green PCR kit and Quantitect Primer Assays (Hs_APOC3_1_SG, QT00012537, Qiagen).
Genotyping
Genomic DNA was isolated and purified from whole blood (EDTA) using a commercial DNA isolation kit (NucleoSpin, Macherey & Nagel, Düren, Germany). Participants were genotyped for the SNPs rs2854116 (À455T4C) and rs2854117 (À482C4T) located in the promoter region of APOC3. The region containing both SNPs was amplified by PCR and sequenced by ABI Prism dye terminator cycle sequencing (Applied Biosystems, Foster City, CA, USA) using the following oligonucleotide primers: 5 0 -TCTCAGCCTTT-CACACTGGA-3 0 and 5 0 -AGAGCTCAGCCCTGTAACCA-3 0 .
Statistical analyses
Results are given as medians and interquartile ranges. For statistical analyses, data that were not normally distributed (for example, liver fat, IS, body fat distribution; Shapiro-Wilk W test) were logarithmically transformed. We performed multivariate linear regression analyses to investigate independent relationships between the parameters. To test the effect of the genotype on gene expression, hepatic triglyceride content, anthropometrics and metabolic characteristics, the parameter to be considered was set as the dependent variable in these analyses and the genotypes were included as independent nominal variables and adjusted for gender, age and total body fat. Similar multivariate linear regression analyses were performed to investigate the effect of the genotype on the changes in relevant metabolic parameters during the intervention. In these models, the change in each parameter was adjusted for its baseline value, gender, age and total body fat at baseline and follow-up. The analyses in the larger population were performed first in all subjects, then in tertiles of waist circumference at baseline. Each tertile consisted of the sum of respective tertile of men and of women. The statistical software package JMP 5.1 (SAS Institute Inc., Cary, NC, USA) was used.
Results
Relationships between hepatic gene expression, triglyceride content and the SNPs in Relationships of the SNPs in APOC3 with anthropometrics and metabolic characteristics The 330 subjects (130 males and 200 females) had a mean age of 45 (range 18-69) years. 21 Very strong negative correlations were found between liver fat and IS (OGTT, r ¼ À0.45, Po0.0001; clamp, r ¼ À0.48, Po0.0001) after adjustment for age, gender and total body fat mass. Neither the SNP À455T4C or the SNP À482C4T were associated with liver fat or IS. In addition, no relationships with adiposity measures, for example, visceral obesity were APOC3, liver fat content and insulin resistance A Peter et al observed (all PX0.13; adjusted for gender, age and total body fat in the dominant model).
We then tested the same relationships combining the genotypes as done in the study by Petersen et al. 31 The genotypes consisting of the homozygous carriers of both major alleles (À455T and À482C) and carriers of the À455C and/or À428T minor alleles were not associated with liver fat content (P ¼ 0.97, Table 1 ) or with IS estimated from the OGTT (P ¼ 0.41). A similar result was found for IS measured by the clamp (P ¼ 0.99). In addition, no significant relationships of the genotypes with fetuin-A, which is involved in the regulation of IS, 40 was found. However, and interestingly, carriers of the minor alleles had higher visceral fat mass and lower circulating adiponectin (Table 1) . We then tested whether the genotypes interact with waist circumference in determining liver fat and metabolic traits. Indeed, the interaction terms of the SNP À455T4C with waist circumference were significant for liver fat (P ¼ 0.033), triglycerides (P ¼ 0.032) and IS assessed during the OGTT (P ¼ 0.045). The interaction of the SNP À482C4T with waist circumference was significant for triglycerides (P ¼ 0.022). We observed similar interactions for the genotypes consisting of the homozygous carriers of both major alleles (À455T and À482C) and carriers of the À455C and/or À428T minor alleles: the interaction terms were significant for liver fat (P ¼ 0.022), serum triglycerides (P ¼ 0.018) and IS estimated from the OGTT (P ¼ 0.029). To depict the interaction effect, we then divided the subjects into tertiles of waist circumference. Carriers of the minor À455C and/or À482T alleles had higher liver fat (P ¼ 0.012), and triglycerides (P ¼ 0.010) only in the lowest, but not in the other tertiles (Table 2, Figure 2 ). In the lowest tertile the genotypes were also associated with higher body weight and higher visceral fat mass and with lower circulating adiponectin ( Table 2) . No consistent genotype effect was found in the other tertiles.
Relationships of the SNPs in APOC3 with changes in anthropometrics and metabolic parameters during the lifestyle intervention In agreement to an earlier analysis in a smaller set of subjects from our ongoing lifestyle intervention, 17 body weight (À3%), total body fat (À10%), visceral fat (À15%), liver fat (À27%), IS (OGTT þ 15%; clamp: þ 19%) and triglycerides (À6%) improved. The SNP À455T4C significantly associated with the change in visceral fat during the intervention (P ¼ 0.03; adjusted for gender, age, visceral fat at baseline and total body fat at baseline and at follow-up). A trend for an association with visceral fat was also found for the À482C4T SNP (P ¼ 0.06). Also the genotypes consisting of the homozygous carriers of both major alleles (À455T and À482C) and carriers of the À455C and/or À428T minor alleles were significantly associated with the change in visceral fat (P ¼ 0.028). No association of either SNP or the genotypes of the SNPs combined with the changes in other parameters was found. When the analyses were performed in tertiles of Figure 1 The relation between APOC3 mRNA expression, hepatic triglyceride content and genetic variation in the APOC3 promoter in 50 human liver biopsies is displayed. The expression of APOC3 mRNA, normalized to b-actin correlates with hepatic triglyceride content (a). Carriers of the minor alleles À455C and/or À428T located in the APOC3 promoter tend to have higher APOC3 mRNA expression (medians and interquartile ranges) (b). Hepatic triglyceride content is not different between carriers of the minor alleles (À455C and/or À482T) and homozygous major allele carriers of both SNPs (medians and interquartile ranges) (c). P-values are for unadjusted parameters.
APOC3, liver fat content and insulin resistance A Peter et al waist circumference, both SNPs as well as the genotypes of the SNPs combined were significantly associated with the changes in visceral fat in the lowest, but not in the other tertiles of waist circumference at baseline (À455T4C: P ¼ 0.014; À482C4T: P ¼ 0.012, combination of SNPs: P ¼ 0.0138). In carriers of the minor À455C or/and À482T APOC3, liver fat content and insulin resistance A Peter et al risk alleles there was a significantly lower reduction of visceral fat compared with the respective major allele homozygotes. The SNP À482C4T and the genotypes of the SNPs combined were also associated with less decrease in liver fat (P ¼ 0.044 and P ¼ 0.09, respectively), in the lowest, but not in the other tertiles of waist circumference. In the lowest tertile the SNPs or the SNPs combined were not associated with changes in body weight (À455T4C: P ¼ 0.38; À482C4T: P ¼ 0.15, combination of SNPs: P ¼ 0.38) or total body fat (À455T4C: P ¼ 0.88; À482C4T: P ¼ 0.77, combination of SNPs: P ¼ 0.88).
Discussion
APOC3 is an interesting candidate that may have a role in the pathogenesis of NAFLD and metabolic diseases. The APOC3 gene is highly expressed in the liver and to a lesser extent in the intestine. [23] [24] [25] By inhibiting lipoprotein lipase activity and triglyceride hydrolysis as well as interfering with binding of apoB100 or apoE to hepatic receptors, APOC3 impairs the clearance of triglyceride-rich particles from the circulation, which results in increased plasma triglyceride concentrations. [23] [24] [25] 41 In mice, overexpression of human APOC3 leads to hypertriglyceridemia, 42 whereas APOC3 deficiency protects from high serum triglyceride levels. 43 In line, humans with a loss-of-function mutation of APOC3 have reduced plasma concentrations of the protein, as well as reduced fasting and postprandial triglyceride concentrations. 44, 45 In addition, direct proinflammatory properties on vascular endothelial cells have been described. 46, 47 Common mutations in the APOC3 promoter (À455T4C and À482C4T), are associated with higher plasma triglyceride [26] [27] [28] and APOC3 concentrations 29 and increased risk of CHD, 26, 28, 30 and, as recently suggested, also hepatic steatosis and insulin resistance. 31 However, the latter two findings could not be confirmed in the Dallas Heart Study and the Atherosclerosis Risk in Communities study. 32 What is a possible explanation for the different results? Interestingly, hepatic APOC3 expression is physiologically inhibited by the action of insulin and its expression and secretion increases in insulin resistant states. 48 The aforementioned SNPs are located in a previously identified insulin response element of the promoter of APOC3. Although the wild-type promoter variant was found to be responsive to the suppressive effect of insulin, the variant promoter was defective in its response to insulin treatment and remained constitutively active at several concentrations of insulin. This loss of insulin regulation was mapped to the polymorphic sites at positions À482 and À455 of APOC3. 0 Figure 2 The influence of genetic variation in the APOC3 promoter (À455T4C and/or À482C4T) on liver fat content measured by 1 HMR spectroscopy in 330 subjects is displayed. Subjects were divided into tertiles of waist circumference. Carriers of the À455C and/or À428T minor alleles in the lowest tertile had higher liver fat (a). No significant effect of À455C and/or À428T minor alleles on liver fat could be detected in the middle (b) or the highest tertile (c). Medians and interquartile ranges; P-values are for unadjusted parameters.
APOC3, liver fat content and insulin resistance A Peter et al absent. In agreement, an interaction between the À455T4C and À482C4T SNPs with IS has been proposed in that the SNPs associated with increased risk of myocardial infarction only in lean and insulin-sensitive subjects but not in insulinresistant subjects with visceral obesity. 34 In addition, in a large study in more than 6000 subjects and in a metaanalysis the risk alleles were associated with type 2 diabetes in more lean but not in more obese subjects. 49 This supports that the APOC3 gene may always be overexpressed in visceral obesity, which is commonly accompanied by insulin resistance, because the suppressive effects of the promoter SNPs are absent. Certainly, it cannot be excluded that the effects of the SNPs are very mild, and are thus diluted in the face of the much greater effect of visceral adiposity on the studied phenotypes. Another possible explanation may be that the capacity of the liver to store fat is not infinite, but probably saturates at some point and, therefore, the impact of the SNPs may become progressively smaller as the capacity of the liver to store fat saturates. This lead us to investigate whether the effects of the SNPs À455T4C and À482C4T in APOC3 on liver fat are modulated by visceral obesity. First, we found that in liver biopsies of our relatively lean subjects with a mean BMI of 25 kg m À2 , APOC3 mRNA expression correlated positively with liver triglyceride content. In agreement with our hypothesis that the effects of the SNPs on APOC3 mRNA expression would be apparent in these individuals, we found a statistical trend for a genotype effect. However, no effect on liver triglyceride content was detectable, indicating that the impact of the genotype on triglyceride content may be small. Again in agreement with our hypothesis, we did not detect a relationship of the genotypes with liver fat in our large population of 330 subjects having a mean BMI of 29.5 kg m À2 and a mean waist circumference of 96.5 cm.
However, a significant interaction of the genotypes with waist circumference was present. In the lowest tertile of waist circumference (mean value: 84.6 cm), the genotypes significantly correlated with liver fat content, as well as with serum triglycerides. Interestingly, in this lower tertile of waist circumference we found a large impact of the genotypes on visceral fat mass, both in cross-sectional and longitudinal analyses, and the adipokine adiponectin. Kozlitina et al. 32 did not detect significant relationships of the SNPs with liver fat in subjects with a BMIo25 kg m
À2
, a finding which somewhat argues against our hypothesis. However, when choosing the same approach, we also did not detect a significant relationship of the SNPs with liver fat in normal weight subjects (P ¼ 0.44). On the other hand, we detected a significant relationship when separating individuals based on visceral obesity. Visceral fat mass is much stronger associated with IS than BMI. 9 Because insulin signaling appears to be involved in the effect of the SNPs on metabolism, separation of individuals by estimates of visceral adiposity may more precisely be able to divide individuals in more insulinsensitive and more insulin-resistant ones, and thereby, disclose the effects of the SNPs on metabolism. In comparison with the Caucasian population in the study by Petersen et al. 31 (mean/ s.d.; 9 ± 5 mU ml À1 ), we had similar mean fasting insulin levels (7 ± 4 mU ml
À1
) in the lowest tertile of waist circumference, which may explain the similar findings on the liver fat content.
When we studied the impact of the genotypes on IS, which was estimated from the OGTT and also measured by the clamp, no significant relationship was found in all subjects. Also in the lowest tertile of waist circumference, although a significant relationship of the genotypes with liver fat was present and liver fat strongly correlated with IS in this tertile (n ¼ 111, r ¼ À0.48, Po0.0001), no relationship of the genotypes with IS was detectable. This finding suggests that accumulation of triglycerides in the liver in carriers of the minor alleles of the SNPs À455T4C and À482C4T in APOC3 does not result in hepatic lipotoxic effects. Thus, under certain conditions triglyceride synthesis may be an adaptive and positive effect, protecting from toxic triglyceride precursors. 21, 33, 50, 51 In conclusion, our data support that in less viscerally obese humans, APOC3 mRNA expression increases in parallel with the increase in liver fat content and depends on genetic variability in APOC3. However, because the impact of the SNPs in APOC3 on liver fat is small and strongly depends on visceral obesity, the gene probably has a minor role in the pathogenesis of fatty liver. Finally, in future it may become very important to study whether APOC3 is a candidate involved in the protection from obesity-induced liver injury.
